{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:20:53Z","timestamp":1784542853458,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fit relapsed\/refractory (R\/R) acute myeloid leukemia (AML) patients usually undergo intensive chemotherapy (IC)-based salvage to bridge them to allogeneic hematopoietic stem cell transplantation (HSCT), but their prognosis remains poor. Azacitidine and venetoclax (AZA\/VEN) are increasingly used as salvage therapy in R\/R AML with encouraging results, although data remain limited. In this study, we evaluated the post-HSCT outcomes of 75\u2009R\/R AML patients from the VENAURA registry who underwent HSCT after AZA\/VEN salvage. After a median follow-up of 16.9 months, the estimated 2-year overall survival (OS) was 61.4% (95% confidence interval [CI]: 49.5\u201368.1%). The 2-year cumulative incidence of relapse (CIR) was 35.1% (95% CI: 20\u201350.2%). The estimated 2-year non-relapse mortality (NRM) rate was 10.6% (95% CI: 9.8\u201323.3%). Cytological response at the end of cycle 1 was independently associated with OS and CIR in multivariate analysis. Comparison with 75 pair-matched patients receiving IC-based salvage prior to HSCT revealed similar OS in both groups. CIR was not significantly higher in AZA\/VEN-treated compared to IC-treated patients; however, there was a trend toward a lower 2-year NRM rate in the AZA\/VEN group. Our data suggest that AZA\/VEN represents a feasible bridge-to-transplant option with a favorable toxicity profile.<\/jats:p>","DOI":"10.1038\/s41409-026-02834-z","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:21:13Z","timestamp":1774340473000},"page":"551-558","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Allogeneic hematopoietic stem cell transplantation after azacitidine and venetoclax salvage in relapsed\/refractory AML: a multicenter real-world study by the French AURAML group"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1486-9873","authenticated-orcid":false,"given":"Urbain","family":"Tauveron-Jalenques","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9033-575X","authenticated-orcid":false,"given":"Gaspar","family":"Aspas Requena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zofia","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1447-8721","authenticated-orcid":false,"given":"Emmanuelle","family":"Tavernier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6741-971X","authenticated-orcid":false,"given":"Pedro","family":"Chor\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Carre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Cornillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Contejean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Rocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Lamure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Mauz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"Thevenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Boullanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Matteo","family":"Pica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Dony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7338-1081","authenticated-orcid":false,"given":"Mauricette","family":"Michallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amine","family":"Belhabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00ebl","family":"Heiblig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"2834_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2834_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2023022481","volume":"143","author":"F Thol","year":"2024","unstructured":"Thol F, D\u00f6hner H, Ganser A. How I treat refractory and relapsed acute myeloid leukemia. Blood. 2024;143:11\u201320.","journal-title":"Blood"},{"key":"2834_CR3","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/ajh.25162","volume":"93","author":"C Ganzel","year":"2018","unstructured":"Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, et al. Very poor long-term survival in past and more recent studies for relapsed AML patients: the ECOG-ACRIN experience. Am J Hematol. 2018;93:1074\u201381.","journal-title":"Am J Hematol"},{"key":"2834_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"2834_CR5","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","volume":"103","author":"I Aldoss","year":"2018","unstructured":"Aldoss I, Yang D, Aribi A, Ali H, Sandhu K, Al Malki MM, et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia. Haematologica. 2018;103:e404\u2013e407.","journal-title":"Haematologica"},{"key":"2834_CR6","doi-asserted-by":"crossref","unstructured":"Feld J, Tremblay D, Dougherty M, Czaplinska T, Sanchez G, Brady C, et al. Safety and efficacy: clinical experience of venetoclax in combination with hypomethylating agents in both newly diagnosed and relapsed\/refractory advanced myeloid malignancies. Hemasphere. 2021; 5:e549.","DOI":"10.1097\/HS9.0000000000000549"},{"key":"2834_CR7","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.3390\/cancers14071734","volume":"14","author":"J Labrador","year":"2022","unstructured":"Labrador J, Saiz-Rodr\u00edguez M, de Miguel D, de La Iglesia A, Rodr\u00edguez-Medina C, Vidriales MB, et al. Use of venetoclax in patients with relapsed or refractory acute myeloid leukemia: the PETHEMA registry experience. Cancers. 2022;14:1734.","journal-title":"Cancers"},{"key":"2834_CR8","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.3390\/cancers14082025","volume":"14","author":"S Garciaz","year":"2022","unstructured":"Garciaz S, Hospital MA, Alary AS, Saillard C, Hicheri Y, Mohty B, et al. Azacitidine plus venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients. Cancers. 2022;14:2025.","journal-title":"Cancers"},{"key":"2834_CR9","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1111\/bjh.18229","volume":"198","author":"O Jamy","year":"2022","unstructured":"Jamy O, Lin K, Worth S, Bachiashvili K, Rangaraju S, Vachhani P, et al. Hypomethylating agent\/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia. Br J Haematol. 2022;198:e35\u2013e37.","journal-title":"Br J Haematol"},{"key":"2834_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1370405","volume":"14","author":"F Angotzi","year":"2024","unstructured":"Angotzi F, Lessi F, Leoncin M, Fil\u00ec C, Endri M, Lico A, et al. Efficacy and safety of venetoclax plus hypomethylating agents in relapsed\/refractory acute myeloid leukemia: a multicenter real-life experience. Front Oncol. 2024;14:1370405. https:\/\/doi.org\/10.3389\/fonc.2024.1370405.","journal-title":"Front Oncol"},{"key":"2834_CR11","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/ajh.27626","volume":"100","author":"C Petit","year":"2025","unstructured":"Petit C, Higue J, Acheaibi Z, Gilhodes J, Hospital MA, Devillier R, et al. Venetoclax-azacitidine versus azacitidine for the treatment of primary refractory or first relapsed acute myeloid leukemia. An IPC-DATAML-MSKCC retrospective study. Am J Hematol. 2025;100:906\u20138.","journal-title":"Am J Hematol"},{"key":"2834_CR12","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41375-024-02501-6","volume":"39","author":"R Shahswar","year":"2025","unstructured":"Shahswar R, Gabdoulline R, Krueger K, Wichmann M, G\u00f6tze KS, Braitsch K, et al. A novel prognostic risk model for patients with refractory\/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents. Leukemia. 2025;39:614\u201322.","journal-title":"Leukemia"},{"key":"2834_CR13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00277-021-04693-8","volume":"101","author":"O Pasvolsky","year":"2022","unstructured":"Pasvolsky O, Shimony S, Ram R, Shimoni A, Shargian L, Avni B, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study. Ann Hematol. 2022;101:379\u201387.","journal-title":"Ann Hematol"},{"key":"2834_CR14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41409-021-01476-7","volume":"57","author":"DA Pollyea","year":"2022","unstructured":"Pollyea DA, Winters A, McMahon C, Schwartz M, Jordan CT, Rabinovitch R, et al. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. Bone Marrow Transpl. 2022;57:160\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"2834_CR15","first-page":"694.e1","volume":"28","author":"AC Winters","year":"2022","unstructured":"Winters AC, Bosma G, Abbott D, Minhajuddin M, Jordan C, Pollyea DA, et al. Outcomes are similar after allogeneic hematopoietic stem cell transplant for newly diagnosed acute myeloid leukemia patients who received venetoclax + azacitidine versus intensive chemotherapy. Transpl Cell Ther. 2022;28:694.e1\u2013694.e9.","journal-title":"Transpl Cell Ther"},{"key":"2834_CR16","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1182\/bloodadvances.2022009632","volume":"7","author":"NJ Short","year":"2023","unstructured":"Short NJ, Ong F, Ravandi F, Nogueras-Gonz\u00e1lez G, Kadia TM, Daver N, et al. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. Blood Adv. 2023;7:3573\u201381.","journal-title":"Blood Adv"},{"key":"2834_CR17","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1007\/s00277-022-04983-9","volume":"101","author":"TT Yang","year":"2022","unstructured":"Yang TT, Song XL, Zhao YM, Ye BD, Luo Y, Xiao HW, et al. Outcome after allogeneic hematopoietic stem cell transplantation following Venetoclax-based therapy among AML and MDS patients. Ann Hematol. 2022;101:2731\u201341.","journal-title":"Ann Hematol"},{"key":"2834_CR18","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.3390\/cancers15061666","volume":"15","author":"SY Bang","year":"2023","unstructured":"Bang SY, Park S, Kwag D, Lee JH, Min GJ, Park SS, et al. A successful bridge therapy combining hypomethylating agents with venetoclax for adult patients with newly diagnosed or relapsed\/refractory acute myeloid leukemia. Cancers. 2023;15:1666.","journal-title":"Cancers"},{"key":"2834_CR19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1182\/bloodadvances.2024013086","volume":"9","author":"JM Unglaub","year":"2025","unstructured":"Unglaub JM, Schlenk RF, Middeke JM, Krause SW, Kraus S, Einsele H, et al. Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed\/refractory AML. Blood Adv. 2025;9:375\u201385.","journal-title":"Blood Adv"},{"key":"2834_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/bjh.20147","volume":"207","author":"Y Ye","year":"2025","unstructured":"Ye Y, Liu X, Dai H, Hu J, Yu G, Zhang Y, et al. Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed\/refractory acute myeloid leukaemia: a multicentre cohort study. Br J Haematol. 2025;207:151\u201361.","journal-title":"Br J Haematol"},{"key":"2834_CR21","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144:2169\u201373.","journal-title":"Blood"},{"key":"2834_CR22","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2834_CR23","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S, B\u00e9n\u00e9 MC, Buccisano F, Cloos J, et al. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131:1275\u201391.","journal-title":"Blood"},{"key":"2834_CR24","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:2753\u201367.","journal-title":"Blood"},{"key":"2834_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4252\/wjsc.v9.i12.227","volume":"9","author":"A Plesa","year":"2017","unstructured":"Plesa A, Dumontet C, Mattei E, Tagoug I, Hayette S, Sujobert P, et al. High frequency of CD34+CD38-\/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia. World J Stem Cells. 2017;9:227\u201334.","journal-title":"World J Stem Cells"},{"key":"2834_CR26","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/bmt.2015.350","volume":"51","author":"N Bleyzac","year":"2016","unstructured":"Bleyzac N, Cuzzubbo D, R\u00e9nard C, Garnier N, Dubois V, Domenech C, et al. Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis. Bone Marrow Transpl. 2016;51:698\u2013704.","journal-title":"Bone Marrow Transpl"},{"key":"2834_CR27","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"2834_CR28","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","volume":"69","author":"HM Shulman","year":"1980","unstructured":"Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204\u201317.","journal-title":"Am J Med"},{"key":"2834_CR29","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transpl. 2015;21:389\u2013401.e1.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2834_CR30","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139.","journal-title":"Blood"},{"key":"2834_CR31","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1182\/blood-2024-210596","volume":"144","author":"PY Dumas","year":"2024","unstructured":"Dumas PY, Bertoli S, Santana C, Heiblig M, Leguay T, Tavitian S, et al. Real-world multicenter comparison of venetoclax and azacitidine versus intermediate or high dose cytarabine-based salvage for patients with AML in first relapse after front-line intensive chemotherapy. Dataml-IPC-Auraml Consortium Study. Blood. 2024;144:4275.","journal-title":"Blood"},{"key":"2834_CR32","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1200\/JCO.2012.46.6193","volume":"31","author":"T Hahn","year":"2013","unstructured":"Hahn T, McCarthy PL Jr, Hassebroek A, Bredeson C, Gajewski JL, Hale GA, et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol. 2013;31:2437\u201349.","journal-title":"J Clin Oncol"},{"key":"2834_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01344-3","volume":"15","author":"J Higu\u00e9","year":"2025","unstructured":"Higu\u00e9 J, Orvain C, Dumas PY, Peterlin P, Hospital MA, Barri\u00e8re S, et al. Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study. Blood Cancer J. 2025;15:141.","journal-title":"Blood Cancer J"},{"key":"2834_CR34","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","volume":"122","author":"RB Walter","year":"2013","unstructured":"Walter RB, Buckley SA, Pagel JM, Wood BL, Storer BE, Sandmaier BM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 2013;122:1813\u201321.","journal-title":"Blood"},{"key":"2834_CR35","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ajh.25211","volume":"93","author":"MH Gilleece","year":"2018","unstructured":"Gilleece MH, Labopin M, Yakoub-Agha I, Volin L, Soci\u00e9 G, Ljungman P, et al. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. Am J Hematol. 2018;93:1142\u201352.","journal-title":"Am J Hematol"},{"key":"2834_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00479-3","volume":"11","author":"MH Gilleece","year":"2021","unstructured":"Gilleece MH, Shimoni A, Labopin M, Robinson S, Beelen D, Soci\u00e9 G, et al. Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT. Blood Cancer J. 2021;11:88.","journal-title":"Blood Cancer J"},{"key":"2834_CR37","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1182\/bloodadvances.2022007168","volume":"6","author":"M Jentzsch","year":"2022","unstructured":"Jentzsch M, Bischof L, Backhaus D, Brauer D, Schulz J, Franke GN, et al. Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission. Blood Adv. 2022;6:4570\u201380.","journal-title":"Blood Adv"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02834-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02834-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02834-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:50:29Z","timestamp":1778154629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02834-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2834"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02834-z","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Emmanuelle Tavernier, Martin Carr\u00e9, J\u00e9r\u00f4me Cornillon, Sylvain Lamure: honoraria for advisory boards (AbbVie). Adrien Contejean: grants (Janssen, BMS, AbbVie), support for attending meetings (Pfizer, Servier). Cl\u00e9ment Rocher: honoraria for advisory boards (BMS), symposia (GSK), and staff (AstraZeneca). Urbain Tauveron-Jalenques, Gaspar Aspas Requena, Zofia Gross, Pedro Chor\u00e3o, Cl\u00e9mence Santana, Natacha Mauz, Ugo Thevenet, Nadine Boullanger, Gian Matteo Pica, Arthur Dony, Mauricette Michallet, Amine Belhabri and Ma\u00ebl Heiblig declare no potential competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}